Nancy Foldvary-Schaefer, DO

Nancy Foldvary-Schaefer, DO
Deparment of Neurology, The Cleveland Clinic Foundation, Cleveland, OH

Cynthia Harden, MD
Weill Cornell Medical College Comprehensive Epilepsy Center, New York, NY

Andrew Herzog, MD
Neuroendocrine Unit at Beth Israel Deaconess Medical Center and the Department of Neurology, Harvard Medical School, Boston, MA

Tommaso Falcone, MD
Department of Obstetrics and Gynecology, The Cleveland Clinic Foundation, Cleveland, OH

Correspondence: Nancy Foldvary-Schaefer, DO, Department of Neurology, Section of Epilepsy, The Cleveland Clinic Foundation, 9500 Euclid Avenue, S51, Cleveland, OH 44195; e-mail: [email protected]

*This article has been excerpted and adapted, with permission, from two previous review articles by these authors:

• Foldvary-Schaefer N, Falcone T. Catamenial epilepsy: pathophysiology, diagnosis, and management. Neurology 2003; 61(6 suppl 2):S2–S15.
• Harden CL. Menopause and bone density issues for women with epilepsy. Neurology 2003; 61(6 suppl 2):S16–S22.

Dr. Foldvary-Schaefer receives grants/research support from the National Institutes of Health, GlaxoSmithKline, UCB Pharma, Medtronic, Shire, and Solvay.

Dr. Harden receives grants/research support from Pfizer, GlaxoSmithKline, and Ivax; is a consultant for GlaxoSmithKline and Novartis; and has received honoraria from Novartis, GlaxoSmithKline, and Ortho-McNeil.

Drs. Herzog and Falcone have indicated they have nothing to disclose.

Nancy Foldvary-Schaefer, DO
Deparment of Neurology, The Cleveland Clinic Foundation, Cleveland, OH

Cynthia Harden, MD
Weill Cornell Medical College Comprehensive Epilepsy Center, New York, NY

Andrew Herzog, MD
Neuroendocrine Unit at Beth Israel Deaconess Medical Center and the Department of Neurology, Harvard Medical School, Boston, MA

Tommaso Falcone, MD
Department of Obstetrics and Gynecology, The Cleveland Clinic Foundation, Cleveland, OH

Correspondence: Nancy Foldvary-Schaefer, DO, Department of Neurology, Section of Epilepsy, The Cleveland Clinic Foundation, 9500 Euclid Avenue, S51, Cleveland, OH 44195; e-mail: [email protected]

*This article has been excerpted and adapted, with permission, from two previous review articles by these authors:

• Foldvary-Schaefer N, Falcone T. Catamenial epilepsy: pathophysiology, diagnosis, and management. Neurology 2003; 61(6 suppl 2):S2–S15.
• Harden CL. Menopause and bone density issues for women with epilepsy. Neurology 2003; 61(6 suppl 2):S16–S22.

Dr. Foldvary-Schaefer receives grants/research support from the National Institutes of Health, GlaxoSmithKline, UCB Pharma, Medtronic, Shire, and Solvay.

Dr. Harden receives grants/research support from Pfizer, GlaxoSmithKline, and Ivax; is a consultant for GlaxoSmithKline and Novartis; and has received honoraria from Novartis, GlaxoSmithKline, and Ortho-McNeil.

Drs. Herzog and Falcone have indicated they have nothing to disclose.

Nancy Foldvary-Schaefer, DO
Deparment of Neurology, The Cleveland Clinic Foundation, Cleveland, OH

Cynthia Harden, MD
Weill Cornell Medical College Comprehensive Epilepsy Center, New York, NY

Andrew Herzog, MD
Neuroendocrine Unit at Beth Israel Deaconess Medical Center and the Department of Neurology, Harvard Medical School, Boston, MA

Tommaso Falcone, MD
Department of Obstetrics and Gynecology, The Cleveland Clinic Foundation, Cleveland, OH

Correspondence: Nancy Foldvary-Schaefer, DO, Department of Neurology, Section of Epilepsy, The Cleveland Clinic Foundation, 9500 Euclid Avenue, S51, Cleveland, OH 44195; e-mail: [email protected]

*This article has been excerpted and adapted, with permission, from two previous review articles by these authors:

• Foldvary-Schaefer N, Falcone T. Catamenial epilepsy: pathophysiology, diagnosis, and management. Neurology 2003; 61(6 suppl 2):S2–S15.
• Harden CL. Menopause and bone density issues for women with epilepsy. Neurology 2003; 61(6 suppl 2):S16–S22.

Dr. Foldvary-Schaefer receives grants/research support from the National Institutes of Health, GlaxoSmithKline, UCB Pharma, Medtronic, Shire, and Solvay.

Dr. Harden receives grants/research support from Pfizer, GlaxoSmithKline, and Ivax; is a consultant for GlaxoSmithKline and Novartis; and has received honoraria from Novartis, GlaxoSmithKline, and Ortho-McNeil.

Drs. Herzog and Falcone have indicated they have nothing to disclose.